Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth

Yoshinori Inagaki(Yokohama University of Pharmacy), Norihiro Kokudo(National Center for Global Health and Medicine)

BioScience Trends

January 1, 2011

10.5582/bst.2011.v5.2.52

Cited by 42

Related Papers

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

|Nature Genetics|2014|780

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

|Gut|2019|720

Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial

|European Journal of Cancer|2021|24

Dissemination of evidence-based clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons and primary care physicians

|Gut|2007|19